Pharmacokinetic properties of indinavir in rat: Some limitations of noncompartmental analysis

Drug Development and Industrial Pharmacy

Volumn 36, Issue 3, 2010, Pages 355-361

  Hamidi, Mehrdad ^a  

^a ZANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Compartmental analysis; HIV protease inhibitors; Indinavir; Noncompartmental analysis; Pharmacokinetics

Indexed keywords

INDINAVIR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MEAN RESIDENCE TIME; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RAT; STEADY STATE;

EID: 77249121645     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903173564     Document Type: Article

References (25)

1. Flexner C. (1998). HIV-protease inhibitors. N Engl J Med, 338:1281-1292
2. Eron JE. (2000). HIV-protease inhibitors. Clin Infect Dis, 30(Suppl. 2):S160-70.
3. Kakuda TN. (1998). Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm, 55:233-254
4. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, et al. (2000). Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society- USA Panel. JAMA, 283:381-390
5. Collier AC, Coombs DA, Schoenfeld, RL, Bassett RL, Timpone J, Baruch A, et al. (1996). Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med, 334:1011-1017
6. Hammer SM, Squires, KE, Hughes, MD, Grimes JM, Demeter LM, Currier JS, et al. (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med, 337:725-733
7. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. (1997). Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med, 337:734-739
8. Acosta EP, Kakuda, TN, Brundage RC, Anderson PL, Fletcher CV. (2000). Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis, 30(Suppl. 2):S151-9.
9. Burger DM, Hoetelmans RMW, Hugen RWH, Mulder JW, Meenhorst PL, Koopmans PP, et al. (1998). Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir Ther, 3:215-220
10. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. (1999). Indinavir concentrations and antiviral effect. Pharmacotherapy, 19:708-712
11. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. (1996). A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS, 10:485-492
12. Shibata N, Matsumura Y, Okamoto H, Kawaguchi Y, Ohtani A, Yoshikawa Y, et al. (2000). Pharmacokinetic interaction between HIV-1 protease inhibitors in rats: Study on combinations of two kinds of HIV-1 protease inhibitors. J Pharm Pharmacol, 52:1239-1246
13. Lin JH, Chiba M, Balani SK, Chen IW, Kwei GY-S, Vastag KJ, et al. (1996). Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos, 24:1111-1120 (Pubitemid 26346225)
14. Lin JH, Chiba M, Chen IW, Nishime JA, Vastag KJ. (1996). Sexdependent pharmacokinetics of indinavir, in vivo and in vitro evidences. Drug Metab Dispos, 24:1298-1306.
15. Chiba M, Hensleigh M, Lin JH. (1997). Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor in rat and human microsomes. Biochem Pharmacol, 53:1187-1195
16. Lin JH, Chiba M, Chen IW, Nishime JA, Florencia A, Yamazaki M, et al. (1999). Effect of dexamethasone on the intestinal firstpass metabolism of indinavir in rats: Evidence of cytochrome P-450 A and P-glycoprotein induction. Drug Metab Dispos, 27:1187-1193
17. Lin JH, Chen IW, Vastag KJ, Ostovic D. (1995). pH-Dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos, 23:730-735
18. Vacca JP, Dorsey BD, Schleif WA, Levin RB, McDaniel SL, Darke PL, et al. (1994). L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor. Proc Natl Acad Sci USA, 91:4096-4100
19. Shargel L, Yu ABC. (1999). Applied biopharmaceutics and pharmacokinetics. Appleton & Lange: Stamford, 607-641
20. Gibaldi M, Perrier D. (1982). Pharmacokinetics. Marcel Dekker Inc.: New York, 409-419
21. Shargel L, Yu ABC. (1999). Applied biopharmaceutics and pharmacokinetics. Appleton & Lange: Stamford, 67-98.
22. Gibaldi M, Perrier D. (1982). Pharmacokinetics. Marcel Dekker Inc.: New York, 45-111.
23. Waynforth HB, Flecknell PA. Experimental and surgical technique in rat. Academic Press: London, 215-222
24. Hamidi M. (2006). Simple and sensitive high-performance liquid chromatography method for the quantitation of indinavir in rat plasma and central nervous system. J Sep Sci, 29:620-627
25. Wagner JG. (1993). Pharmacokinetics for the pharmaceutical scientist. Technomic Publishing Co.: Lancaster, 83-102.